GlobeNewswire·Nov 5, 2026, 4:05 PM ET

Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results

Organogenesis Holdings Inc. reported a third-quarter 2026 net revenue of $45.5 million, a 70% decrease from $150.5 million in the same period of 2025.
Advanced Wound Care revenue fell 73% to $38.2 million, while Surgical & Sports Medicine revenue declined 19% to $7.3 million.
The company recorded a net loss of $29.6 million for the quarter, compared to a net income of $21.6 million in Q3 2025.
Adjusted net loss for the quarter was $29.3 million, and adjusted EBITDA loss was $22.4 million.
Gross profit margin decreased to 52% from 76% in the prior year quarter, driven by a $90.7 million drop in gross profit.
Operating expenses decreased 42% to $74.9 million, primarily due to reductions in selling, general, and administrative expenses.
For the nine months ended September 30, 2026, net revenue was $124.5 million, a 63% decline from $338.0 million in the prior period.
Nine-month net loss totaled $179.1 million, compared to a net loss of $6.7 million in the same period of 2025.
Cash, cash equivalents, and restricted cash stood at $26.9 million as of September 30, 2026, down from $94.3 million at the end of 2025.
The company updated its 2026 fiscal year revenue guidance to a range of $179.4 million to $200.0 million, reflecting a 65% to 68% decline from 2025.
The revenue decline was attributed to market reset conditions, LCD regulatory changes causing inventory write-downs, facility closures, restructuring activities, and R&D program terminations.